Defining A Competitive Next-Gen RNA Therapeutic In 2024

By Anna Rose Welch, Editorial & Community Director, Advancing RNA

In the broader advanced therapies space, going from zero to millions of patients in a short period of time is a commercial dynamic we have yet to encounter. Thanks to the myriad scientific and technical hurdles in making cell and gene therapies, we’ve had to start small and incrementally plan for greater access and larger patient populations much farther down the road.